138 related articles for article (PubMed ID: 10184948)
1. Atypical antipsychotics and formulary decisions.
Am J Manag Care; 1998 Jan; 4 Suppl():S8-12; discussion S12-4. PubMed ID: 10184948
[TBL] [Abstract][Full Text] [Related]
2. The impact of schizophrenic patient functionality on service utilization and cost. Based on a presentation by Sandra L. Tunis, PhD.
Am J Manag Care; 1999 Jul; 5(10 Suppl):S583-90. PubMed ID: 10539493
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N; Foster RH; Olney R; Plosker GL
Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
[TBL] [Abstract][Full Text] [Related]
4. Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
Foster RH; Goa KL
Pharmacoeconomics; 1999 Jun; 15(6):611-40. PubMed ID: 10538333
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
[TBL] [Abstract][Full Text] [Related]
6. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
Almond S; O'Donnell O
Pharmacoeconomics; 2000 Apr; 17(4):383-9. PubMed ID: 10947493
[TBL] [Abstract][Full Text] [Related]
7. [Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia++ in Spain].
Sacristán JA; Gómez JC; Salvador-Carulla L
Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1997; 25(4):225-34. PubMed ID: 9412161
[TBL] [Abstract][Full Text] [Related]
8. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.
Hamilton SH; Revicki DA; Edgell ET; Genduso LA; Tollefson G
Pharmacoeconomics; 1999 May; 15(5):469-80. PubMed ID: 10537964
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia.
Glazer WM; Johnstone BM
J Clin Psychiatry; 1997; 58 Suppl 10():50-4. PubMed ID: 9265917
[TBL] [Abstract][Full Text] [Related]
10. A cost-effectiveness clinical decision analysis model for schizophrenia.
Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
[TBL] [Abstract][Full Text] [Related]
11. [Economic comparison of olanzapine versus haloperidol in treatment of schizophrenia in France].
Le Pen C; Lilliu H; Allicar MP; Olivier V; Gregor KJ
Encephale; 1999; 25(4):281-6. PubMed ID: 10546082
[TBL] [Abstract][Full Text] [Related]
12. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
Bounthavong M; Okamoto MP
J Eval Clin Pract; 2007 Jun; 13(3):453-60. PubMed ID: 17518814
[TBL] [Abstract][Full Text] [Related]
13. Switching antipsychotic medications.
Weiden PJ; Aquila R; Dalheim L; Standard JM
J Clin Psychiatry; 1997; 58 Suppl 10():63-72. PubMed ID: 9265919
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia.
Revicki DA
Schizophr Res; 1999 Mar; 35 Suppl():S101-9. PubMed ID: 10190231
[TBL] [Abstract][Full Text] [Related]
15. [Economic analyses of olanzapine in the treatment of schizophrenia and bipolar disorder].
Dilla T; Prieto L; Ciudad A; Sacristán JA
Actas Esp Psiquiatr; 2004; 32(5):269-79. PubMed ID: 15529211
[TBL] [Abstract][Full Text] [Related]
16. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
Kongsakon R; Leelahanaj T; Price N; Birinyi-Strachan L; Davey P
J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic research evidence.
Revicki DA
Curr Opin Investig Drugs; 2001 Jan; 2(1):110-7. PubMed ID: 11527002
[TBL] [Abstract][Full Text] [Related]
18. Atypical antipsychotics in the managed care era.
Loebel AD; Botts SR; Feldman BI
Am J Manag Care; 1998 Jan; 4 Suppl():S37-50; quiz S51-2. PubMed ID: 10181074
[TBL] [Abstract][Full Text] [Related]
19. Impact of newer antipsychotics on outcomes in schizophrenia.
Keks NA
Clin Ther; 1997; 19(1):148-58; discussion 126-7. PubMed ID: 9083717
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.
Tunis SL; Faries DE; Nyhuis AW; Kinon BJ; Ascher-Svanum H; Aquila R
Value Health; 2006; 9(2):77-89. PubMed ID: 16626411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]